Mirtazapin 1 A Pharma (Mirtazapine)

Mirtazapine is used to treat depressive disorders and related conditions.

• Major depressive disorder: reduces depressive symptoms and improves overall mood.
• Depressive episodes in bipolar disorder: helps manage the depressive phase under specialist supervision.
• Anxiety symptoms co‑occurring with depression: can alleviate anxiety and improve sleep quality.

• Mirtazapine acts as an antagonist at central presynaptic α2‑adrenergic receptors, increasing the release of norepinephrine and serotonin. It also blocks postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic transmission while reducing associated side effects. These mechanisms lead to a net increase in neurotransmitter signaling that contributes to its antidepressant effect.

Mirtazapine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Sedation or drowsiness
• Increased appetite and weight gain
• Dry mouth
• Constipation
• Dizziness
• Somnolence

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia
• Seizures
• Serotonin syndrome, especially with other serotonergic agents
• Suicidal thoughts or worsening depression, particularly early in treatment
• Severe allergic reactions such as anaphylaxis
• Hepatotoxicity (rare)

When prescribing mirtazapine, clinicians should consider several safety precautions to minimize risks.

• Monitor weight: patients may experience significant weight gain and should have regular weight checks.
• Assess for suicidal ideation: especially during the initial weeks of therapy.
• Evaluate hepatic function: dose adjustment may be needed in severe liver impairment.
• Caution with CNS depressants: concurrent use can increase sedation and respiratory depression.
• Avoid abrupt discontinuation: tapering is recommended to reduce withdrawal symptoms.
• Store below 25°C: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use can precipitate serotonin syndrome.
• Other serotonergic agents (SSRIs, SNRIs, triptans, linezolid): risk of serotonin syndrome.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase mirtazapine plasma levels.
• CNS depressants (alcohol, benzodiazepines): may enhance sedation and respiratory depression.
• Anticholinergic drugs: additive anticholinergic burden may worsen side effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (rifampin, carbamazepine): may reduce mirtazapine concentrations.
• Antihypertensive agents: additive hypotensive effect may occur.
• NSAIDs or anticoagulants: increased risk of gastrointestinal bleeding.
• Lithium: may increase risk of neurotoxicity.
• Oral contraceptives: may slightly raise mirtazapine levels.